1. What Is the IL-23 Inhibitors Market?
The IL-23 Inhibitors Market covers biologic therapies selectively targeting the p19 subunit of interleukin-23 to suppress Th17 immune pathway activation across inflammatory skin and gastrointestinal diseases. Dermatologists and gastroenterologists deploy IL-23 selective inhibitors for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis with expanding indications under investigation. The market includes guselkumab, risankizumab, tildrakizumab, mirikizumab, and emerging pipeline selective p19 inhibitors.
2. IL-23 Inhibitors Market Size & Forecast
3. Emerging Technologies
- IL-23 inhibitor indication expansion into hidradenitis suppurativa, atopic dermatitis, and other inflammatory conditions extending the addressable patient population.
- Subcutaneous autoinjector formulations enabling home administration with minimum clinic visit burden for maintenance therapy.
- Biosimilar IL-23 inhibitor development in early stages as lead agents approach extended patent protection periods.
- AI-powered biomarker selection identifying IL-23 pathway activation biomarkers predicting exceptional response to selective p19 inhibition.
Such innovations are driving change across adjacent industries too. Discover more in our Il 17 Inhibitors Market.
4. Key Market Opportunity
Gastroenterology IBD indication expansion represents the largest commercial growth opportunity for multi-indication IL-23 inhibitor assets. Psoriasis first-line biologic positioning building on head-to-head superiority data is the largest dermatology prescribing growth opportunity. The multi-indication positioning across dermatology and gastroenterology creates the largest commercial scope for leading IL-23 inhibitor assets.
5. Top Companies in the IL-23 Inhibitors Market
The following organisations hold leading positions in the IL-23 Inhibitors Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- AbbVie
- Johnson and Johnson
- Eli Lilly
- Leo Pharma
- Almirall
- UCB
- Novartis
- Bristol Myers Squibb
- Boehringer Ingelheim
- Samsung Bioepis
6. Market Segmentation
The IL-23 Inhibitors Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Clinical Generation | Established IL-23 p19 Inhibitors Next-Generation IL-23 Inhibitors Pipeline p19 Novel Formats |
| By Indication | Plaque Psoriasis Crohn's Disease Ulcerative Colitis Psoriatic Arthritis Hidradenitis Suppurativa |
| By Dosing Frequency | Monthly Induction Quarterly Maintenance Biannual Maintenance |
| By Treatment Line | First-Line Biologic Second-Line After TNF Failure Third-Line Refractory Therapy |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the IL-23 Inhibitors Market trajectory over the forecast period:
Gastroenterology indication expansion is the most significant IL-23 inhibitor growth driver as risankizumab and mirikizumab approvals in Crohn's disease and ulcerative colitis add substantial new prescribing populations.The IBD indications create cross-specialty IL-23 inhibitor prescribing across dermatology and gastroenterology driving combined market growth substantially above dermatology-only projections. The indication breadth creates competitive differentiation for agents with both skin and gut approvals.
Convenient dosing regimens are creating physician and patient preference advantages for IL-23 inhibitors versus competing biologic mechanisms.Quarterly subcutaneous maintenance dosing with guselkumab and risankizumab reduces treatment burden substantially versus monthly or biweekly dosing requirements of IL-17 and TNF inhibitors. The dosing convenience is creating sustained prescribing preference particularly among patients prioritizing treatment burden reduction.
Head-to-head clinical superiority data is establishing IL-23 inhibitors as preferred biologic choice in dermatology.Guselkumab ECLIPSE trial superiority versus secukinumab and risankizumab IMMerge head-to-head versus secukinumab are providing systematic clinical evidence supporting IL-23 inhibitor prescribing preference in psoriasis. The clinical superiority data is driving formulary positioning gains across private and public payer systems.
For related market intelligence, see the Psoriasis Biologics Market.
8. Segmental Analysis
By agent, the risankizumab segment dominated the IL-23 Inhibitors Market in 2025, as AbbVie Skyrizi with approved indications across plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis represents the broadest indication coverage of any IL-23 inhibitor sustaining the largest multi-specialty prescribing volume globally.
By indication, the Crohn's disease segment is projected to register the highest growth rate through 2034, as gastroenterology IL-23 inhibitor adoption in moderate-to-severe Crohn's disease is the fastest-growing indication driving systematic commercial expansion.
9. Regional Analysis
Regional demand patterns across the IL-23 Inhibitors Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the IL-23 Inhibitors Market in 2025, accounting for around 46 percent of global revenue. The United States dermatology and gastroenterology prescribing infrastructure drives substantial IL-23 inhibitor utilization. Johnson and Johnson guselkumab and AbbVie risankizumab generate substantial U.S. commercial revenue across psoriasis and IBD indications. Moreover, U.S. specialty pharmacy infrastructure supports efficient multi-indication IL-23 inhibitor distribution.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the IL-23 Inhibitors Market through 2034. The region's expanding dermatology and gastroenterology infrastructure combined with growing biologic access is driving substantial IL-23 inhibitor adoption. Japanese regulatory approvals and Korean dermatology prescribing are driving regional market growth. Chinese IL-23 inhibitor market expansion combined with domestic biologic development is creating substantial regional commercial activity.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The IL-23 Inhibitors Market was valued at USD 8.47 Bn in 2025 and is projected to reach USD 26.70 Bn by 2034, growing at a CAGR of 13.6% over the 2026–2034 forecast period.
The IL-23 Inhibitors Market is projected to grow at a CAGR of 13.6% from 2026 to 2034.
North America dominated the IL-23 Inhibitors Market in 2025, accounting for around 46 percent of global revenue.
The leading companies in the IL-23 Inhibitors Market include AbbVie, Johnson and Johnson, Eli Lilly, Leo Pharma, Almirall, UCB, Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Samsung Bioepis.
Gastroenterology indication expansion is the most significant il-23 inhibitor growth driver as risankizumab and mirikizumab approvals in crohn's disease and ulcerative colitis add substantial new prescribing populations.
By agent, the risankizumab segment dominated the IL-23 Inhibitors Market in 2025, as AbbVie Skyrizi with approved indications across plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis represents the broadest indication coverage of any IL-23 inhibitor sustaining the largest multi-specialty prescribing volume globally.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 4 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 4 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 4 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.